A Phase 1, open-label, single-dose study to evaluate the effect of moderate or severe renal impairment on the pharmacokinetics of inavolisib
Latest Information Update: 07 Dec 2023
At a glance
- Drugs Inavolisib (Primary)
- Indications Colorectal cancer; HER2 negative breast cancer; HER2 positive breast cancer; Solid tumours; Squamous cell cancer
- Focus Pharmacokinetics
- Sponsors Roche
- 24 Nov 2023 New trial record